Please login to the form below

Not currently logged in

TEVA's tardive dyskinesia drug wins FDA breakthrough status

SD-809 to be given development incentives

TEVA's tardive dyskinesia drug, SD-809 has been granted breakthrough therapy designation by the FDA.

The designation comes on the back of data from the phase II/III Aim to Reduce Movements in Tardive Dyskinesia (ARM-TD) study which enrolled 117 patients with moderate to severe degrees of the condition.

Michael Hayden, president of global R&D and chief scientific officer at TEVA, said: “The granting of breakthrough therapy designation by the FDA represents significant progress toward advancing the clinical program for SD-809, as a potential, much-needed treatment option for the underserved tardive dyskinesia patient population.

“We remain excited about studying this innovative compound across a number of indications.”

Tardive dyskinesia is a condition characterised repetitive and uncontrollable movements of the tongue, lips, face and extremities and has been associated with the use of anti-psychotic drugs.

The condition affects around 500,000 people in the United States.

Breakthrough Therapy Designation is granted to a drug that is intended to treat a serious condition and preliminary clinical evidence suggests that SD-809 (deutetrabenazine) may demonstrate substantial improvement over available therapy. 

Article by
Nikhil Patel

10th November 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?